Introduction
Until recently, stem cells from adult tissues have been thought to differentiate exclusively into cell types of their tissue of origin. Evidence is now accumulating that at least some stem cells may differentiate down alternative pathways when introduced into a regenerating environment. One of the first indications that this might occur came from studies in which whole bone marrow was transplanted into lethally irradiated recipients and allowed to engraft and reconstitute the hematopoietic system. After injury introduced into the tissue of interest, donor-derived cells were found to be incorporated into the regenerated tissue. After transplanting bone marrow marked with a LacZ transgene expressed under the control of a muscle-specific promoter, 1 Ferrari et al found ␤-galactosidase-positive muscle fibers 2 weeks after a necrotizing injury was induced with cardiotoxin. Although the LacZ-positive muscle fibers were very rare (around 0.1-0.01%), their data clearly indicated that cells from the bone marrow could migrate to the site of injury and participate in skeletal muscle repair.
This work was followed by other reports that cells from the bone marrow could differentiate into cardiac muscle, 2 endothelial cells, 3 osteoblasts, 4 liver cell types, [5] [6] [7] and neuronal 8, 9 and non-neuronal 10 brain. The bone marrow contains many cell types, and it was not clear which cells could account for the multiple activities. In addition to the differentiated cell types that comprise the bone marrow (eg stroma, vascular cells, adipocytes, osteoblasts and osteoclasts), both mesenchymal stem cells and hematopoietic stem cells (HSC) reside within the marrow and are transferred during bone marrow transplantation. Therefore, these multiple cell types that were found to be donor-derived after bone marrow transplantation could have originated from either of these stem cell types, or potentially other precursors. While these data generated excitement about the possibility that multiple cell types could be generated from one type of stem cell, the HSC, similar data with highly purified stem cells, and ultimately clonal analysis, are necessary to confirm this. Below, we will review the evidence that HSC can generate cardiomyocytes and endothelial cells, in addition to hematopoietic cells.
Hematopoietic stem cells
HSC have been characterized in mice and humans by cell sorting and transplantation. They reside in the bone marrow in adults and, via a population of committed progenitors, constantly replenish the differentiated cells of the peripheral blood. In the mouse, HSC can be highly enriched or purified using a combination of cell surface markers such as the stem cell antigen, Sca-1, 11 the tyrosine kinase receptor c-Kit 12 and low or negative levels of lineage markers (lin Ϫ/low ). 13 Alternatively, HSC can be highly enriched using fluorescent vital dyes such as Hoechst 33342 which are actively effluxed from primitive cells, 14 thus defining the so-called side population, or 'SP'.
Using these purification strategies alone or in combination, populations of highly purified and homogeneous murine HSC can be obtained, and the hematopoietic potential of these populations has been extensively characterized. Human HSC have been isolated primarily through their expression of the marker CD34, 15 lack of lineage markers and low expression levels of Thy1, 16 although there is also evidence for a CD34-negative HSC precursor. 17, 18 Although over the years, the ability of HSC to give rise to stromal cell types resident in the marrow has been debated, the dogma that HSC can only give rise to hematopoietic cells has stood until recently.
Vascular fates of circulating and marrowderived precursors
Unlike the continuous process of blood regeneration in adults, the generation of new blood vessels is thought to occur only in response to tissue injury or growth, such as during wound healing, and in pregnancy and lactation. Pathological processes including tumorigenesis and atherosclerosis, on the other hand, are associated with the synthesis, mobilization and/or activation of growth factors, cytokines and proteases that stimulate abnormal vascular cell replication and migration. The ensuing pathological vascularization plays a central role in the progression of such prevalent diseases. 19 It was previously thought that new blood vessels formed during postnatal neovascularization, in normal and pathological conditions, were solely derived from the pre-existing vasculature. The process of sprouting or remodeling of established vessel structures, to form new ones, is referred to as angiogenesis. 20 Recent studies, however, indicate that vascular cell progenitors are present in blood circulation 21, 22 and resident in bone marrow, 23, 24 and contribute to blood vessel formation during tissue repair and in pathological conditions. Furthermore, the neovascularization process that involves the coalescence of circulating and marrow-derived precursors, is thought to more closely resemble embryonic vasculogenesis rather than angiogenesis. 25 
Endothelial cells
Precursors to vascular endothelial cells in adults were first identified in blood circulation 26 and have been shown to engraft into vascular endothelium to a level of 10%. 27 Progenitors isolated from bone marrow have reported incorporation rates ranging from~3 23 to 25%. 24 Such contributions of adult vascular progenitors to injury-induced neovascularization have been associated with enhanced blood flow, 28 and improved function 24 of ischemia-damaged tissues.
The apparent variation of engraftment efficiency of isolated progenitors can be due to the fact that the majority of the precursor populations in blood and bone marrow are heterogeneous, and some likely contain a higher proportion of cells committed to a vascular lineage versus hematopoietic or other cell lineage. Interestingly, more heterogeneous populations tend to engraft to a higher degree into vessel structures. Therefore, it may also be that highly purified populations do not contain other cell Gene Therapy types that provide instructive signals to the multipotent progenitors. Thus, the molecular phenotype of true vascular progenitor cells, and the mechanisms by which they are induced to become vascular cells in vivo, remain to be determined. Such insights are necessary to effectively direct the fate of adult stem cells for vascular cell and gene therapy.
Toward this goal, we examined the vascular potential of SP cells, highly enriched for HSC, 14 from adult mouse bone marrow. After bone marrow transplantation and cardiac injury, we found LacZ-marked endothelial progeny of SP cells in vessels in the region of injury repair. 23 This is intriguing given that developmental studies suggest hematopoietic and endothelial cells share a common precursor, 29 and may suggest such relationships can be retained in the adult. To prove definitively that a single SP cell can generate both hematopoietic and endothelial cells, clonal analysis of transplanted cells, 30 or retroviral lineage marking 31,32 must be performed. In support of the potential relationship between marrow SP cells and endothelial progenitors, we have found some similarities in the phenotype of adult bone marrow SP cells 23 and embryonic hemangioblasts. 33 Importantly, bone marrow-derived SP cells do not express genes reflective of mature endothelial cells (Flt-1, VE-cadherin, von Willebrand factor, factor VIII), smooth muscle cells (SM-␣-actin, calponin, SM22␣) or cardiac muscle cells (␣-actinin, desmin). 23 Bone marrow-derived SP cells do, however, express some genes shared by embryonic hematopoietic and vascular cell progenitors, including PE-CAM-1 34 and Tal-1. 35 Surprisingly, other genes thought to be specifically reflective of an embryonic blood and endothelial cell progenitor, such as CD34 36 and tyrosine kinase receptor Flk-1 33 are not expressed in SP cells. However, expression of the Flk-1 ligand, VEGF-A, is detected. 23 Bone marrow SP cells, as HSC, are predisposed to differentiate into hematopoietic cells, but with some lower efficiency can generate endothelial cells after an injury. If cells with similar potential can be reproducibly isolated from adult human bone marrow and their vascular potential enhanced by ex vivo manipulation, the development of autologous cell and gene therapy strategies to modulate postnatal neovascularization and hematopoiesis will be accelerated.
Smooth muscle cells
Evidence that endothelial cell progenitors reside in blood circulation and bone marrow is increasing. Such evidence of the existence of similar mural cell (smooth muscle cell and pericyte) progenitors has been slower to accumulate, perhaps reflecting a lower frequency. Vascular smooth muscle cells and pericytes were previously thought to be recruited via endothelial-derived signals 37, 38 from local mesenchyme in the region of neovascularization, or recruited along with endothelial cells from pre-existing vessels 39 to form the surrounding vessel wall as new vessels sprout. However, recent findings suggests that blood circulation also contains a smooth muscle cell progenitor population. 40 The molecular identity of the circulating mural cell precursor remains to be determined. It must also be determined whether endothelial and mural cells arise from a common progenitor in blood and bone marrow. A recent study of embryonic stem cells provides evidence that this may be the case. Yamashita and coworkers 34 found that embryonic stem cells expressing the VEGF receptor Flk-1, which is expressed early in vascular development by hemangioblasts, as well as mature endothelial cells, 33 give rise to vascular smooth muscle cells in vivo and in vitro. These studies suggest that stem cells identified in adult tissues as endothelial cell precursors may serve as smooth muscle cell precursors, as well. Isolation and characterization of distinct progenitor cell types, along with investigation of their vascular potential in vivo, are needed to address this issue.
Cardiac fates of circulating and marrowderived precursors
Relative to the regeneration of blood and blood vessels, regeneration of cardiac tissue is far less frequent. The heart is one of the few organs of the body that does not appear to contain a resident stem cell population on call to repair damage, although there is some evidence to the contrary. 41 Perhaps this is why cardiovascular disease, resulting in chronic ischemia and myocyte degeneration, is among the leading causes of death.
Since adult cardiac tissue appears unable to adequately repair itself in response to injury, several attempts have been made to use other cell types to generate adult cardiac myocytes. The cell populations examined include fetal and neonatal cardiac myocytes, [42] [43] [44] skeletal myoblasts, 45 and cardiomyocytes differentiated from embryonic stem cells. 46 These pioneering studies using skeletal myoblasts or neonatal myocytes directly injected into or grafted on to injured hearts improved contractile strength, but failed to produce cardiac myocytes that are electrically coupled to pre-existing muscle fibers. 45 While grafted mouse fetal cardiomyocytes appeared to form intercalated disks with adjacent cells and were electrically coupled, they are not a practical source of cardiac tissue for clinical use. 42 More recent studies have focused on the use of bone marrow-derived cells as a renewable and readily accessible source for generating cardimyocytes. In Orlic and coworkers' studies, 47 GFP-marked bone marrow cells enriched for HSC were injected directly into heart tissue that had immediately before undergone coronary artery ligation, producing an ischemic region. Nine days after transplantation, the injected regions displayed large numbers of GFP-marked cells which expressed cardiac myosin and some of which had markers of immature cardiomyocytes. In another study involving the direct injection of marrow-derived progenitors into injured hearts, 24 decreased apoptosis of cardiomyocytes and improved cardiac function was reported. In this case, the beneficial effects of the transplanted marrow-derived cells were attributed to enhanced neovascularization, and not direct regeneration of cardiac myocytes.
In our studies, LacZ-marked bone marrow SP cells were first stably engrafted into the hematopoietic system via bone marrow transplantation. Two to 4 weeks after cardiac injury consisting of coronary artery occlusion followed by reperfusion, sections of the heart revealed LacZpositive cells that lacked hematopoietic markers and instead expressed ␣-actinin, indicative of a cardiac muscle fate. 23 As discussed above, marked cells were also found in vascular endothelium. Engraftment was primarily found in the repairing region adjacent to the induced fibrotic scar. While these studies suggest that SP cells or their progeny can migrate to the site of injury and participate in cardiac repair, further studies are needed to assess both the functional integration of the participating cells and the exact cell types involved, whether migrating HSC or other progenitors. Engraftment levels observed in our model were low: around 0.02% of cardiomyocytes were derived from the SP cells, which is too low to significantly contribute to functional restoration of the injured tissue. However, methods that increase the presence of the progenitors at the site of injury, or increase the differentiation to cardiomyocytes may prove useful as adjunct therapy to existing strategies.
Along these lines, Orlic and co-workers reported that G-CSF administered several days before and following myocardial infarction in mice reduced both infarct size and mortality. 48 They propose that this is due to G-CSFmediated mobilization of a stem cell population from the bone marrow to the site of injury. However, secondary effects of G-CSF administration, such as perhaps increased numbers of red blood cells and hence oxygen perfusion of the tissue, could have similar effects. The use of mobilized stem cells that are marked with a transgene or retrovirus should reveal the basis of the G-CSF effect. Regardless of its mechanism of action, since G-CSF is already approved for clinical use, its use in patients at high risk for myocardial infarction is already being explored in clinical trials.
While several stem cell sources have now been shown to be capable of generating cardiomyocytes, their clinical utility will depend on a variety of factors, including efficiency of generation of tissue and accessibility of the stem cell population. The isolation of human embryonic stem cells 49 and their propensity to differentiate into cardiac muscle 50 make these cells an important potential source. In addition, marrow-derived hematopoietic progenitors, as well as mesenchymal stem cells 51 are potential sources. Further characterization of both the stem cells and the engrafted cells is essential, as well as an evaluation of the contribution of engrafted cells to improved function.
Harnessing the potential of adult stem cells for autologous cell and gene therapy
Adult stem cells are, by definition, capable of becoming a variety of differentiated cell types in vivo. Although stem cells derived from adult tissues have not been definitively shown to exhibit pluripotent capabilities like their embryonic counterparts, their accessibility for autologous therapies in adult patients offers them a distinct advantage over embryonic stem cells. The keys to harnessing the potential of these progenitors will be reproducible isolation, characterization, and direction toward specific fates in vitro and in vivo. In addition, the engraftment levels currently observed will have to be enhanced for maximum utility. This will likely come from better understanding of both the environmental factors that allow engraftment in an injured site, as well as signals that draw stem cells into the regeneration process, either from the circulation or from local residence. In addition, improvements in efficiency of engraftment can result from modification of the stem cells; understanding the mechanisms involved may allow us to selectively direct the fate to specific lineages of interest.
Directing the fate of multipotent bone marrow-derived progenitors specifically toward hematopoietic, vascular or cardiac cell fates can only be accomplished if the phenotype of the stem cells is defined, and their homing and differentiation programs are elucidated. Although much has been learned in recent years about the genes that regulate these cell lineages in the embryo, virtually nothing is known about the molecular profile of progenitors in the adult or whether insights gained from embryonic systems can be directly applied to the manipulation of adult progenitors. Finally, manipulation of stem cells ex vivo offers the opportunity of introducing genes of therapeutic value before transplantation. Some stem cell types may be more readily transducible than others, so study in this area is also warranted. We may ultimately have several powerful options for cadiovascular cell and gene therapy.
